What are you looking for?

Library
Poster
Full Title

Assessment of Mitochondrial Function Following Long-Term Treatment of Human Bronchial Epithelial Cells with Total Particulate Matter from a candidate Modified-Risk Tobacco Product versus Cigarettes


Authored by  M Van der Toorn, D Malińska*, J Szymanski*, J Walczak*, M Prill*, K Drabik*, B Michalska*, A Wojtala*, P Patalas-Krawczyk*, M Partyka*, S Johne, A Sewer, E Guedj, K Luettich, M Peitsch, J Hoeng, M Wieckowski*, J Szczepanowska*, J Duszynski*

Presented at Tenth World Congress - Alternatives and Animal Use in the Life Sciences    
* This author is not affiliated with PMI.
Alt Animal Use 2017 VanderToorn Assessment of mitochondrial function following long term treatment Screenshot2
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts to develop and assess products that have the potential to reduce individual risk and population harm associated with tobacco use. This site is for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not for advertising or marketing. It is not intended for use by consumers.

Our RRPs

Reduced-risk products ("RRPs") is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continued smoking. We have a range of RRPs in various stages of development, scientific assessment and commercialization. Because our RRPs do not burn tobacco, they produce an aerosol that contains far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.